Sat, Jan 31, 2015, 4:37 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • martha.varias martha.varias Mar 18, 2013 6:10 PM Flag

    Corporate Development:

    "Inovio continues to advance discussions with large pharmaceutical companies with the goal of securing strategic partnerships to advance the development of SynCon® vaccines.

    In 2012 Inovio expanded its existing license agreement with the University of Pennsylvania with worldwide rights to technology and intellectual property for novel synthetic vaccines against C. difficile (intestinal infections), Wilms' tumor gene (leukemia and various solid tumor types), and Ebola virus and the family of Filovirus such as Marburg (which could potentially be used in bioterror attacks).

    Inovio received U.S. patents covering its synthetic consensus influenza H1 and cervical dysplasia/cancer SynCon® DNA vaccine constructs, adding to its patent estate of more than 400 worldwide granted and pending patents.

    We were awarded a U.S. Department of Defense Small Business Innovation Research Grant to advance a low-cost, non-invasive surface electroporation delivery device and test its utility in combination with Inovio synthetic vaccines against viruses with bioterrorism potential.

    Our VGX Animal Health subsidiary reported advancements for its growth hormone releasing hormone (GHRH) treatment focused on enhancing health and food production efficiency of farm animals. Previously approved in Australia, the Company was granted marketing approval in New Zealand for its high-dose plasmid therapy. The Company also reported that its new low-dose version of this therapy, LifeTide® SW 1.0, resulted in more live pigs per litter and higher birth and weaning weights."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • If smarthough/bokhore/ etc spent some much time to make 19 negative ratings (one is from jerrycurls), then we have to give more attention to the above part of the recent 10-K.

    • Bump over bash

    • Just a press release here... More important is the actions taken by management to help the negotionations with big pharma. The recent rais of 14 mil shores up their balance sheet which is important, it lets big pharma know they cannot wait until Ino is desperate for cash to negotiate, INO now has over 14 months of cash on hand. Now the upcoming vote at the shareholder meeting on allowing the company to issue more shares of stock allows the company to dilute if needed. For example, if a company wanted to put in 50 million they would pretty much own the company. In that case the company would dilute to allow room for that capital. Also, it is a Poison Pill against hostile take overs. For example, a company aquires over 5% then says they intend to take over the company in a hostile manor (hostile takeover) the board could then issue more shares and dilute the hostile party down to a smaller non controlling position. The fact the company feels the need to get this in place shows they expect some positive results. Now lets just hope they are right!

      Sentiment: Strong Buy

    • btw there is an update on this. i found it at Mickael's twitter:

      "INO is advancing discussions with large pharmaceutical companies regarding a prospective partnership. While Inovio knows that there is no partnership until one has been agreed upon and entered in to, some companies have already entered into discussions with INO not based on efficacy data (which is not yet available) but based on immune response data. Management believes that this is notable. Larger pharmaceutical companies would commonly want to wait until they could actually see efficacy data before pursuing a partnership."

      Sentiment: Strong Buy

    • The key thing in the report IMO is the fact that it doesn't state a delay in Hep C phase 2 interim data. It says they still expect the data in Q1 2013. if they were gonna announce a delay today would have been the time to do it. Seems in a few days or so we will see the Hep C data.

      Sentiment: Strong Buy

8.34-0.160(-1.88%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.